132 related articles for article (PubMed ID: 30447346)
1. Inactivation of SMARCA2 by promoter hypermethylation drives lung cancer development.
Wu J; He K; Zhang Y; Song J; Shi Z; Chen W; Shao Y
Gene; 2019 Mar; 687():193-199. PubMed ID: 30447346
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of Aristaless-like homeobox-4, a potential tumor suppressor gene associated with lung cancer.
Liu WB; Han F; Du XH; Jiang X; Li YH; Liu Y; Chen HQ; Ao L; Cui ZH; Cao J; Liu JY
Int J Cancer; 2014 Mar; 134(6):1311-22. PubMed ID: 24037716
[TBL] [Abstract][Full Text] [Related]
3. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
4. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.
Guerrero-Martínez JA; Reyes JC
Sci Rep; 2018 Feb; 8(1):2043. PubMed ID: 29391527
[TBL] [Abstract][Full Text] [Related]
5. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.
Wu YH; Tsai Chang JH; Cheng YW; Wu TC; Chen CY; Lee H
Oncogene; 2007 Jul; 26(33):4761-73. PubMed ID: 17325666
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of helicase-like transcription factor by promoter hypermethylation in human gastric cancer.
Leung WK; Yu J; Bai AH; Chan MW; Chan KK; To KF; Chan FK; Ng EK; Chung SC; Sung JJ
Mol Carcinog; 2003 Jun; 37(2):91-7. PubMed ID: 12766908
[TBL] [Abstract][Full Text] [Related]
7. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers.
Xie XM; Zhang ZY; Yang LH; Yang DL; Tang N; Zhao HY; Xu HT; Li QC; Wang EH
Int J Oncol; 2013 Nov; 43(5):1636-42. PubMed ID: 24002585
[TBL] [Abstract][Full Text] [Related]
8. Increase in the frequency of p16INK4 gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53.
Seike M; Gemma A; Hosoya Y; Hemmi S; Taniguchi Y; Fukuda Y; Yamanaka N; Kudoh S
Clin Cancer Res; 2000 Nov; 6(11):4307-13. PubMed ID: 11106248
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of CCND2 in Lung and Breast Cancer Is a Potential Biomarker and Drug Target.
Hung CS; Wang SC; Yen YT; Lee TH; Wen WC; Lin RK
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30308939
[TBL] [Abstract][Full Text] [Related]
10. SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptosis by transcriptional activating p53 in lung cancer.
Han F; Liu W; Jiang X; Shi X; Yin L; Ao L; Cui Z; Li Y; Huang C; Cao J; Liu J
Oncogene; 2015 Aug; 34(33):4391-402. PubMed ID: 25435374
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation profiling identifies the HOXA11 gene as an early diagnostic and prognostic molecular marker in human lung adenocarcinoma.
Li Q; Chen C; Ren X; Sun W
Oncotarget; 2017 May; 8(20):33100-33109. PubMed ID: 28380439
[TBL] [Abstract][Full Text] [Related]
12. Identification of
Kartaloglu EB; Oztepe M; Akgun O; Acun T; Ari F; Uz-Yildirim E
Anticancer Res; 2023 Jul; 43(7):3029-3036. PubMed ID: 37351969
[TBL] [Abstract][Full Text] [Related]
13. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.
Yue W; Dacic S; Sun Q; Landreneau R; Guo M; Zhou W; Siegfried JM; Yu J; Zhang L
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4336-44. PubMed ID: 17671114
[TBL] [Abstract][Full Text] [Related]
14. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
15. Identification of Methylation-Driven, Differentially Expressed STXBP6 as a Novel Biomarker in Lung Adenocarcinoma.
Lenka G; Tsai MH; Lin HC; Hsiao JH; Lee YC; Lu TP; Lee JM; Hsu CP; Lai LC; Chuang EY
Sci Rep; 2017 Feb; 7():42573. PubMed ID: 28198450
[TBL] [Abstract][Full Text] [Related]
16. Frequent aberrant methylation of the promoter region of sterile alpha motif domain 14 in pulmonary adenocarcinoma.
Sun W; Iijima T; Kano J; Kobayashi H; Li D; Morishita Y; Okubo C; Anami Y; Noguchi M
Cancer Sci; 2008 Nov; 99(11):2177-84. PubMed ID: 18823374
[TBL] [Abstract][Full Text] [Related]
17. Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma.
Oshimo Y; Oue N; Mitani Y; Nakayama H; Kitadai Y; Yoshida K; Chayama K; Yasui W
Int J Cancer; 2004 Jun; 110(2):212-8. PubMed ID: 15069684
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of the GATA genes in lung cancer.
Guo M; Akiyama Y; House MG; Hooker CM; Heath E; Gabrielson E; Yang SC; Han Y; Baylin SB; Herman JG; Brock MV
Clin Cancer Res; 2004 Dec; 10(23):7917-24. PubMed ID: 15585625
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer.
Zhao G; Qin Q; Zhang J; Liu Y; Deng S; Liu L; Wang B; Tian K; Wang C
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S301-11. PubMed ID: 22552606
[TBL] [Abstract][Full Text] [Related]
20. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
